• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,802.90 -607.08
( -0.78%)
Global Indices
Nasdaq
51,585.70 72.15
(0.14%)
Dow Jones
7,521.58 80.48
(1.08%)
Hang Seng
70,971.12 -82.37
(-0.12%)
Nikkei 225
10,357.71 -41.99
(-0.40%)
Forex
USD-INR
94.39 -0.12
(-0.13%)
EUR-INR
108.40 -1.03
(-0.94%)
GBP-INR
125.08 -1.43
(-1.13%)
JPY-INR
0.59 0.00
(-0.50%)

EQUITY - MARKET SCREENER

SKM Egg Products Export (India) Ltd
Industry :  Food - Processing - Indian
BSE Code
ISIN Demat
Book Value()
532143
INE411D01023
75.1917964
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SKMEGGPROD
12.19
1247.52
EPS(TTM)
Face Value()
Div & Yield %
19.43
5
0
 

radhagobind commercial ltd
Lupin launches generic hypertension drug in the US
Jun 17,2026
The product is bioequivalent to Edarbi of Azurity Pharmaceuticals and is indicated for the treatment of hypertension in adults to lower blood pressure.

Lupin said it is the exclusive first-to-file applicant for the product and is eligible for 180 days of generic drug exclusivity in the US market.

According to IQVIA MAT April 2026 data, Azilsartan Medoxomil Tablets had estimated annual sales of USD 53.5 million in the United States.

Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapeutic segments. The company’s consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25.

Shares of Lupin shed 0.91% to close at Rs 2,256.25 on the BSE.